Truist lowered the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $25 but keeps a Buy rating on the shares. Despite the unfortunate patient death from the MAGNITUDE trial, there is still a path forward for nex-Z given the “complex medical history” of this greater than 80 year old receiving the drug, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat
- Intellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright
- Intellia Therapeutics presents Phase 1/2 data on lonvo-z
- Intellia Therapeutics’ Earnings Call: Progress Amid Challenges
- Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed